BioSpace News Archive

Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates, today announced plans to prioritize its pipeline to focus on the development of VTP-300 in CHB and VTP-1000 in celiac disease.

Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that it intends to offer and sell, subject to market and other conditions, $300.0 million of shares of its common stock in an underwritten public offering.

Connect Biopharma Holdings Limited announced the appointments of Barry Quart, Pharm.D., as Chief Executive Officer and Director, David Szekeres as President, and Kleanthis G. Xanthopoulos, Ph.D., as the new Chair of the Board of Directors.

Connect Biopharma Holdings Limited announced that the Board of Directors, including all of the independent directors of the Board, granted to Barry Quart, Pharm.D., the Company’s newly-appointed Chief Executive Officer, and David Szekeres, the Company’s newly-appointed President, non-qualified stock option awards to purchase an aggregate of 2,658,734 ordinary shares and 1,772,489 ordinary shares, respectively.

Surrozen, Inc. announced publication of data in eLife highlighting the potential to enhance Wnt-signal activation in new targeted SWEETS bispecific antibodies which utilize a unique protein degradation platform that provides alternatives for future clinical applications.

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced upcoming presentations at the 2nd Annual Obesity & Weight Loss Drug Development Summit and the 5th Annual RNA Editing Summit, both taking place in Boston on June 11-13 and June 18-20, respectively.

To support the future implementation of workflow automation in cell therapy production, Thermo Fisher Scientific introduces the Thermo Scientific™ Heracell™ VIOS™ 250i AxD CO2 Incubators.

MIB Agents, a leading pediatric osteosarcoma nonprofit dedicated to Making It Better for its community of patients, caregivers, doctors, and researchers, announced that since its inception in 2016, it has awarded over $1.9 million to scientists across the country through its OutSmarting Osteosarcoma grant program.

Tonix Pharmaceuticals Holding Corp., a fully-integrated biopharmaceutical company, announced it has entered into a placement agency agreement for the purchase and sale of 3,753,558 shares of its common stock at an offering price of $1.065 per share.

Revive Therapeutics Ltd. announced today an update on the Type C meeting written responses received by the Company from the U.S. Food & Drug Administration (“FDA”) for the evaluation of a proposed clinical study of Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for Long COVID (the “Study”).